Intelligence Feed event · Macro · 2026-09-24

    Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease

    Question

    Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease

    Direct answer

    Ionis Pharmaceuticals delivered positive Phase III clinical readouts for two late-stage pipeline assets. In the FUSION trial, ulefnersen met its primary endpoint in FUS-ALS, leading partner Otsuka to prepare regulatory submissions. Simultaneously, the IMAgINATION trial evaluating sefaxersen in patients with IgA nephropathy met its primary efficacy hurdle with statistically significant reductions in proteinuria, clearing a key milestone for commercial progression.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/ionis-reports-positive-phase-iii-trial-results-for-partnered-drugs-in-als-and-ki-cf1268

    MACRO
    Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease
    Ionis Pharmaceuticals delivered positive Phase III clinical readouts for two late-stage pipeline assets. In the FUSION trial, ulefnersen met its primary endpoint in FUS-ALS, leading partner Otsuka to prepare regulatory submissions. Simultaneously, the IMAgINATION trial evaluating sefaxersen in patients with IgA nephropathy met its primary efficacy hurdle with statistically significant reductions in proteinuria, clearing a key milestone for commercial progression.
    IONS
    Impact
    74
    SEP 24
    SIG
    90%
    IONS
    Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease
    Ionis Pharmaceuticals delivered positive Phase III clinical readouts for two late-stage pipeline assets. In the FUSION trial, ulefnersen met its primary endpoint in FUS-ALS, leading partner Otsuka to prepare regulatory submissions. Simultaneously, the IMAgINATION trial evaluating sefaxersen in patients with IgA nephropathy met its primary efficacy hurdle with statistically significant reductions in proteinuria, clearing a key milestone for commercial progression.
    → Positive Phase III clinical endpoints trigger regulatory filing pathways and future commercial milestone royalties for IONS and distribution partners.
    Impact
    Ionis Pharmaceuticals delivered positive Phase III clinical readouts for two late-stage pipeline assets. In the FUSION trial, ulefnersen met its primary endpoint in FUS-ALS, leading partner Otsuka to prepare regulatory submissions. Simultaneously, the IMAgINATION trial evaluating sefaxersen in patients with IgA nephropathy met its primary efficacy hurdle with statistically significant reductions in proteinuria, clearing a key milestone for commercial progression.
    Affected
    IONS
    Transmission
    Positive Phase III clinical endpoints trigger regulatory filing pathways and future commercial milestone royalties for IONS and distribution partners.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IONSpipeline de-risking and commercialization milestone realizationUp1-5dIonis announced positive phase III results for two partnered programs: ulefnersen in FUS-ALS and sefaxersen in IgAN.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSUpagreed43.81 2026-09-24+1.57%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month